2021
DOI: 10.3906/sag-2005-410
|View full text |Cite
|
Sign up to set email alerts
|

Perspectives for immune plasma treatment of COVID-19

Abstract: Background/aim The SARS-CoV-2 infection was declared as a pandemic by the World Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already surpassed that of many previous epidemics. A wide variety of treatment options are being considered for COVID-19, but there is still no definitive treatment or vaccine. This study aims to explain the background of convalescent plasma (CP) treatment and its relations with COVID-19 immunit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 29 publications
0
3
0
Order By: Relevance
“…In another study, 103 patients with severe or life-threatening COVID-19 were randomly assigned to receive standard treatment with or without CP (114). Among the subset of patients who had severe but not life-threatening diseases, the rate of clinical improvement was more significant with immune plasma (115).…”
Section: Current Treatment Strategies Convalescent Immune Plasmamentioning
confidence: 99%
“…In another study, 103 patients with severe or life-threatening COVID-19 were randomly assigned to receive standard treatment with or without CP (114). Among the subset of patients who had severe but not life-threatening diseases, the rate of clinical improvement was more significant with immune plasma (115).…”
Section: Current Treatment Strategies Convalescent Immune Plasmamentioning
confidence: 99%
“…6 The use of CP for treating COVID-19 is highly controversial. 7 Ye et al administered CP to six patients infected with SARS-CoV-2 and reported a rapid and dramatic improvement in patients who presented lung infiltration. 8 It was also reported that CP improved two patients with acute respiratory distress syndrome (ARDS) due to COVID-19.…”
Section: Introductionmentioning
confidence: 99%
“…From the 10-14th day forward, the concentration decreases as a consequence of the immune response that justify the therapeutic use of convalescence plasma at an early stage of severe COVID-19 [4]. Positive serology can suggest an early, active, or late phase of the disease.…”
mentioning
confidence: 99%